-
Express treatment only once a week! Long-acting hemophilia therapy qualified for FDA Priority Review
Time of Update: 2022-09-08
S. FDA has granted it priority review of the hemophilia A drug efanesoctocog alfa (BIVV001), which it co-developed.
S. FDA has granted it priority review of the hemophilia A drug efanesoctocog alfa (BIVV001), which it co-developed.
-
Cancer Treat Rev: Therapeutic strategies for diffuse large B-cell lymphoma
Time of Update: 2022-09-07
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL). Anti-CD20 monoclonal antibody (moAb) rituximab combined with chemotherapy significantly improved the out
-
Slow Shower Treasure Book Mini Program Released: Li Jianyong and Professor Xu Wei take you to the fresh experience
Time of Update: 2022-09-07
Professor Li Jianyong and Professor Xu Wei launched the "Slow Dipping Treasure Book" mini program offline Chronic lymphocytic leukemia/micro-lymphocytic lymphoma (CLL/SLL) is a cloned proliferative t
-
Hematology: Outcomes and risk factors for hemorrhagic cystitis across different transplant sources and conditions in pediatric allogeneic hematopoietic stem cell transplant recipients with severe aplastic anemia
Time of Update: 2022-09-07
Severe aplastic anemia (SAA) is a life-threatening form for which allogeneic hematopoietic stem cell transplantation (allo-HSCT) and immunosuppressive therapy (IST) are available treatments, of which hemorrhagic cystitis (HC) is an allo - Potentially life-threatening complications after HSCT, clinically, HC is characterized by hematuria, dysuria, symptoms of urinary tract irritation, and even renal failure due to hydronephrosis .
-
Hematology: Efficacy and safety of isavuconazole in the prevention of invasive fungal infections in the hematology setting
Time of Update: 2022-09-07
Original source:Ping Y, Hongmei J, Bellmann C, Inês M, Macmillan T, Webb N, Aram JA, Penack O.
2022 Dec;27(1):723 -732.
2022 Dec;27(1):723 -732.
2022 Dec;27(1):723 -732.
2022 Dec;27(1):723 -732.
2022 Dec;27(1):723 -732.
-
"Tearful" red blood cells, have you noticed?
Time of Update: 2022-09-06
For example, in our case, individual teardrop-shaped red blood cells were found in the peripheral blood smear and bone marrow smear, which provided important information for clinical diagnosis in time .
-
subclavian steal syndrome
Time of Update: 2022-09-06
In most cases, the radial artery and blood pressure of the affected side quickly returned to normal after surgery, and the symptoms of cerebral and upper limb ischemia were also rapidly improved .
-
The effect of smear cells on the classification of white blood cells and their role in morphological diagnosis
Time of Update: 2022-09-06
brief summary(i)In this case, the instrument classification lymphatic ratio is significantly increased and the appearance of a large number of smeared cells in the peripheral blood smear gives us a more intuitive prompt, from the blood picture, bone marrow image characteristics are not difficult to point to the diagnosis of lymphocyte proliferative diseases, flow immunotype results confirm the morphological judgment.
-
Intolerance and low response to commonly used antiplatelet drugs?
Time of Update: 2022-09-06
Antiplatelet drug intolerance refers to the situation that patients cannot insist on taking one or more antiplatelet drugs for a long time due to possible or existing adverse reactions of antiplatelet
-
TRANSFUSION: risk of early intravenous bolus of 2 g and 4 g of tranexamic acid in patients with severe traumatic bleeding compared with placebo: a secondary analysis of a randomized, double-blind, placebo-controlled, single-center trial
Time of Update: 2022-09-06
Randomized clinical trials have not screened patients with severe traumatic injury for the risk of thromboembolism (TE) due to tranexamic acid (TXA).
Randomized clinical trials have not screened patients with severe traumatic injury for the risk of thromboembolism (TE) due to tranexamic acid (TXA).
-
Lancet Haematol: Association between nonanaemic iron deficiency and outcome after elective cardiac surgery (IDOCS): a prospective cohort study
Time of Update: 2022-09-06
Overall, among non-anaemic adults undergoing elective cardiac surgery, the study results showed that iron-deficient patients did not experience a reduction in the number of days surviving and staying at home on postoperative day 30 compared with patients with normal iron status .
-
Sustained high fever, leukemia actually remission?
Time of Update: 2022-09-06
A case report of bone marrow natural remission in children with acute monocytic leukemia and literature review [J].
A case report of bone marrow natural remission in children with acute monocytic leukemia and literature review [J].
-
Express $1.1 billion capsule received Phase 2/3 clinical therapy, Novo Nordisk expands the blood disease pipeline
Time of Update: 2022-09-06
Resources:[1] Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders.
▎ WuXi AppTec content team editor▲ Etavopivat molecular structural formula (Image source: PubChem)Resources:[1] Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders.
-
JCI: Scientists discover a specific inflammatory signal associated with leukemia progression
Time of Update: 2022-09-06
Recently, in a research report titled "Bone marrow confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia" published in the international journal Journal of Clinical Investigation, scientists from Northwestern University and other institutions through research The discovery that an inflammatory signaling protein called interleukin-6 may be involved in the progression of acute myeloid leukemia may provide a potential target that could help researchers develop new treatments for AML in the future .
-
Eye-opening: a case of hemophilic femoral pseudotumor with pathological fracture
Time of Update: 2022-09-06
Post-traumatic X-ray films showed the fracture of the cortical bone defect in the middle of the femur, the broken ends were displaced and overlapped, the localized soft tissue mass-like density was enlarged compared with the previous one, and the edge was clear .
-
Sub-Journal of Blood: Assessing risk factors for deep vein thrombosis associated with natural anticoagulants and fibrinomodulin
Time of Update: 2022-09-06
Protein C (PC), protein S (PS), antithrombin III (AT-III), thrombin-activated fibrinolysis inhibitor (TAFI) and plasminogen activator inhibition were measured in patients and controls Agent-1 (PAI-1) .
Protein C (PC), protein S (PS), antithrombin III (AT-III), thrombin-activated fibrinolysis inhibitor (TAFI) and plasminogen activator inhibition were measured in patients and controls Agent-1 (PAI-1) .
-
Living ≠ life, so that patients can return to normal life, this is what we are pursuing
Time of Update: 2022-09-01
Anxiety at the time of diagnosis, collapse at the time of recurrence, standardization at the time of initial treatment, seriousness in maintenance, determination when returning to society, the mental
-
IMS 2022 Voice of China 1q21 acquisition is an independent poor prognostic factor in newly diagnosed multiple myeloma patients
Time of Update: 2022-09-01
Patients with 1q21 acquisition detected a higher proportion of complex karyotypes and copy number abnormalities (CNVs), accompanied by significant 1p32 deletions, as detected by cytoscan involving the CKS1B gene, and were both intermediate and high-risk groups according to the PI definition (p<0.
-
Standardized evaluation of coagulation dysfunction in critically ill patients, see the consensus of Chinese experts!
Time of Update: 2022-08-20
More than 40% of critically ill patients will develop coagulation dysfunction. Early identification of coagulation dysfunction and accurate assessment of coagulation function are the prerequisites and
-
Express progression-free survival is better than standard therapy, and BCMA-targeted CAR-T therapy reaches the primary endpoint of Phase 3 clinical trials
Time of Update: 2022-08-20
▎Edited by WuXi AppTec Content TeamBristol-Myers Squibb (BMS) and 2seventy bio today jointly announced that their chimeric antigen receptor (CAR) T-cell therapy Abecma (idecabtagene viccleucel) is in the treatment of KarMMa-3 in patients with relapsed or refractory multiple myeloma (RRMM).
